This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gemignani, F. Search for Related Content PubMed PubMed Citation Articles by Gemignani, F.

Polymorphisms of the Dopamine Receptor Gene DRD2 and Colorectal Cancer Risk

¹ International Agency for Research on Cancer, Lyon, France; ² Genetica, Dipartimento Scienze Uomo Ambiente, University of Pisa, Pisa, Italy; ³ Institut Catala d'Oncologia, Hospitalet, Barcelona, Spain; and ⁴ Laboratori d'Estadistica i Epidemiologia, Facultat de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain

Requests for reprints: Federico Canzian, Genome Analysis Team, IARC, 150 Cours Albert Thomas, 69372 Lyon 08, France. Phone: 33-4-72738698; Fax: 33-4-72738388. E-mail: canzian{at}iarc.fr

Sporadic colorectal cancer is considered a multifactorial disease in which multiple exposures interact with the individual genetic background resulting in risk modulation. Recent experimental data suggest a role of dopamine and dopamine receptors in the control of proliferation of the cells of colon and gastrointestinal tract. To investigate whether polymorphisms within dopamine receptors genes could have a role in modulating the risk of sporadic colorectal cancer, we did a case-control association study and genotyped 370 cases and 327 controls for seven single-nucleotide polymorphisms (SNP) of DRD2 (–141Cdel, 957T>C, TaqIB, TaqIA, 1412A>G, S311C, and 3208G>T) by a microarray-based technique. Three SNPs within DRD2 were associated with colorectal cancer, with a maximum odds ratio of 2.28 (95% confidence interval, 1.38-3.76) for carriers of the functional SNP –141Cdel. The haplotype which includes –141Cdel, together with the variants 957C and 1412G, shows an odds ratio of 2.86 (95% confidence interval, 1.58-5.18), as compared with the most frequent haplotype. The SNPs within DRD2 associated with colorectal cancer are known to be related to reduced levels of D2 dopamine receptor. Thus, our data point to a possible role of dopamine receptor DRD2 in modulating the risk of colorectal cancer. Future studies on dopamine receptor–mediated signal transduction may provide new insight into the mechanisms of colorectal cancer and suggest new therapeutic strategies.